Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany.

F Griesinger, M Pérol, N Girard, I Durand-Zaleski, S Zacharias, L Bosquet, M Jänicke, X Quantin, A Groth, A Fleitz, A Calleja, S Patel, L Lacoin, M J Daumont, J R Penrod, R Carroll, D Waldenberger, D Reynaud, M Thomas, C Chouaid, 2022.

Lung Cancer, Volume 172, 2022, Pages 65-74. https://doi.org/10.1016/j.lungcan.2022.08.001.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: - / Journal: Lung Cancer
CRISP
2022
Significance of Patient-Reported Outcomes for Metastatic Breast Cancer Patients.

Hillebrand L, E, Söling U, Marschner N, 2022.
Oncol Res Treat 2022;45:423-429. doi: 10.1159/000521826

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: - / Journal: Oncology Research and Treatment
Projektübergreifend
2022
Real-world patient-reported outcomes of breast cancer or prostate cancer patients receiving antiresorptive therapy for bone metastases: Final results of the PROBone registry study.

A Jakob, M-O Zahn, A Nusch, T Werner, R Schnell, M Frank, N Hamm, K-U Däßler, C Losem, M Welslau, P Hoevel, K Potthoff, 2022.

Journal of Bone Oncology, Volume 33, 2022. https://doi.org/10.1016/j.jbo.2022.100420

Indikation: Breast Cancer, Mammakarzinom, Prostatakarzinom, Prostate Cancer / Veranstaltung: - / Journal: Journal of Bone Oncology
PRO Bone
2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world.

Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M; TPK-Group (Tumour Registry Pancreatic Cancer). FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world.
Int J Cancer. 2022

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TPK
2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma – A novel validated prognostic score to facilitate treatment decision-making in real-world.

Marschner N, Hegewisch-Becker S, Reiser M, von der Heyde E, Bertram M, Hollerbach SH, Kreher S, Wolf T, Binninger A, Chiabudini M, Kaiser-Osterhues A, Jänicke M; TPK-Group (Tumour Registry Pancreatic Cancer), 2023.

Int J Cancer. 152:458-469. doi: 10.1002/ijc.34271. Epub 2022 Sep 22.

Link

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: - / Journal: International Journal of Cancer
TPK
2022
Sequential treatment patterns over time for advanced renal cell carcinoma – Data from the German research platform CARAT.

Goebell, P.J., Grüllich, C., Müller, L., Bögemann, M., Martens, U., von der Heyde, E., Reichert, D., Nusch, A., Schlenska-Lange., A., Wetzel, N., Koska, M., Jänicke, M., Marschner, N., Staehler, M., Grünwald, V., 2022.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: IKCS / Journal: -
CARAT
2023
Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials.

Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K, 2022.

European Journal of Haematology, Volume 108, Issue 2, p. 133-144, 2022.
https://doi.org/10.1111/ejh.13719

Indikation: Multiple Myeloma, Multiples Myelom / Veranstaltung: / Journal: European Journal of Hematology
POSEIDON
2022
Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).

Moehler M, Folprecht G, Heinemann V, Holch JW, Maderer A, Kasper S, Hegewisch-Becker S, Schröder J, Overkamp F, Kullmann F, Bechstein WO, Vöhringer M, Öllinger R, Lordick F, Geißler M, Schulz-Abelius A, Linz B, Bernhard H, Paul A, Schmidtmann I, Potthoff K, Schimanski CC, 2021.

International Journal of Cancer, 2021.
https://doi.org/10.1002/ijc.33881

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: / Journal: International Journal of Cancer
LICC
2021
First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study.

Müller V, Ruhnke M, Hoffmann O, Grafe A, Tomé O, Fett W, Bruch HR, Sommer-Joos AK, Schneeweiss A, 2021.

The Breast, Volume 60, P70-77, 2021.
DOI:https://doi.org/10.1016/j.breast.2021.08.014

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: / Journal: The Breast
AVANTI
2021
First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study.

Dechow T, Riera-Knorrenschild J, Hackanson B, Janssen J, Schulz H, Chiabudini M, Fischer von Weikersthal L, Budweiser S, Nacke A, Taeuscher D, Welslau M, Potthoff K, 2021

Cancer Medicine, Volume 10, Issue 22, p. 8127-8137, 2021.
http://doi.org/10.1002/cam4.4310

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: / Journal: Cancer Medicine
NEPTUN
2021